M. Copeman

Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.

T. Venables, R. Newland, A. C. Patel, 1997, Scandinavian journal of gastroenterology.

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

P. Gibbs, L. Lipton, J. Zalcberg, 2013, Cancer Chemotherapy and Pharmacology.

Bmc Clinical Pharmacology Renal Safety of Zoledronic Acid with Thalidomide in Patients with Myeloma: a Pharmacokinetic and Safety Sub-study

S. Cremers, A. Roberts, H. Schran, 2022 .

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

J. Reynolds, A. Schwarer, Z. Rudzki, 2004 .

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

D. Bowtell, J. Zalcberg, M. Millward, 2006, British Journal of Cancer.

Bisphosphonate infusions: patient preference, safety and clinic use

K. Pittman, M. Schou, G. Richardson, 2004, Supportive Care in Cancer.

Two omeprazole‐based Helicobacter pylori eradication regimens for the treatment of duodenal ulcer disease in general practice

M. Copeman, M. Turbitt, I. Mason, 1997, Alimentary pharmacology & therapeutics.